Table 2.

Diagnostic performance for ACS (a), NSTEMI (b), all AMI (c) and MACE after 2 months (d) of HsTnT analysed 3–4 h

a) ACS prediction at 3–4 h	Sensitivity	Specificity	NPV	PPV
n = 77	(95 % CI)	(95 % CI)	(95 % CI)	(95 % CI)
HsTnT
>14	88 (78–94)	38 (32–44)	90 (83–95)	32 (26–35)
>20	81 (70–88)	58 (52–65)	90 (84–90)	39 (31–47)
>30	77 (65–85)	75 (69–80)	91 (86–94)	50 (41–59)
b) NSTEMI prediction at 3–4 h
n = 61
HsTnT
>14	100 (93–100)	39 (33–45)	100 (95–100)	28 (22–35)
>20	93 (83–98)	59 (53–65)	97 (93–99	36 (28–44)
>30	90 (79–96)	75 (69–80)	97 (93–99)	47 (37–56)
c) All AMI prediction at 3–4 h
n = 81
HsTnT
>14	100 (94–100)	41 (35–48)	100 (95–100)	36 (32–43)
>20	94 (85–98)	63 (56–69)	97 (92–99)	45 (37–53)
>30	90 (80–95)	80 (73–84)	96 (92–98)	58 (49–67)
d) MACE prediction at 3–4 h
n = 86
HsTnT
>14	91 (83–96)	39 (33–46)	93 (85–97)	35 (29–42)
>20	83 (73–90)	60 (54–66)	91 (85–95)	42 (35–51)
>30	77 (66–85)	77 (70–81)	90 (85–94)	53 (44–63)

TnT high-sensitivity troponin T, AMI acute myocardial infarction, NSTEMI non-ST-elevation myocardial infarction

All AMI includes NSTEMI and Type 2 AMI. MACE, NSTEMI, non-elective PCI, non-elective CABG and death within 2 months